Rajiv Nayar

Dr. Rajiv Nayar is the Founder and President of HTD Biosystems, a leading Contract Research Organization (CRO) specializing in drug product development for protein and vaccine formulations, lyophilization processes, and advanced drug delivery systems. HTD Biosystems partners with emerging biotechnology companies worldwide to accelerate innovation and product development. Prior to founding HTD Biosystems, Dr. Nayar held senior leadership roles at Bayer, where he established and directed the Formulation and Drug Delivery Group within the biotechnology division. He led global efforts in developing protein- and peptide-based therapeutics across Bayer’s international network, earning three consecutive Presidential Achievement Awards for implementing continuous improvement practices in pharmaceutical development. Dr. Nayar is an inventor on 28 patents and has authored more than 70 scientific publications. He is also the lead inventor of Bayer’s albumin-free Factor VIII formulation, commercialized as Kogenate® FS. Earlier in his career, Dr. Nayar was part of the Canadian Liposome Company, where he contributed to the development of liposomal anticancer therapeutics, including doxorubicin (Myocet®) and vincristine (Marqibo®). Dr. Nayar earned his Ph.D. in Biochemistry from the University of British Columbia and completed an MRC Fellowship at the M.D. Anderson Tumor Institute.